580 results
8-K
EX-2.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
of Schedule 4;
“Losses” means in relation to any matter, all liabilities, losses, claims, Tax, costs, fees and expenses relating to that matter including … is actually required to account to the relevant Tax Authority in respect thereof, including for the avoidance of doubt through the netting
7153497 v5
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
26 Dec 17
Regulation FD Disclosure
12:00am
subsidiaries, including CyDex Pharmaceuticals, Inc., unless the context otherwise provides.
Item 7.01 Regulation FD Disclosure
On December 22, 2017, the Tax … Cuts and Jobs Act (the “TCJA”) was signed into federal law, which among other changes reduces the federal corporate tax rate to 21%. Ligand
8-K
EX-2.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
Real Property
Section 5.13
Tax Matters
Section 5.14
Absence of Changes
Section 5.15
Material Contracts
Section 5.16
Labor Relations
Section 5.17 … Liabilities
Section 6.8
Litigation and Proceedings
Section 6.9
Tax Matters
Section 6.10
Absence of Changes
Section 6.11
Brokers’ Fees
Section 6.12
Proxy
POS AM
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
21 Mar 03
Prospectus update (post-effective amendment)
12:00am
FEDERAL INCOME TAX CONSIDERATIONS.................38
LEGAL MATTERS...........................................................45
EXPERTS … . For a discussion of the tax treatment of a holder receiving
common shares upon surrendering notes for conversion, see "Certain US federal
income tax
POS AM
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
12 Feb 04
Prospectus update (post-effective amendment)
12:00am
.......................................38
DIVIDEND POLICY............................................................38
CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS … number of full shares of common
stock into which any note is converted, together with any cash payment for
fractional shares. For a discussion of the tax
8-K
lpncy8k6e7sq
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
POS AM
4h524h5
18 Jun 03
Prospectus update (post-effective amendment)
12:00am
8-K
EX-99.1
9fyntpjb 4r99qra8s80
4 May 22
Ligand Reports First Quarter 2022 Financial Results
4:03pm
8-K/A
EX-99.2
i43shd
10 Dec 20
Financial Statements and Exhibits
4:13pm
8-K
EX-2.1
72wy66c ka
5 Mar 19
Entry into a Material Definitive Agreement
5:16pm
8-K
EX-99.1
2bzkb8sobvu57jqwlf
6 Mar 19
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:06pm
SC TO-T
EX-99
87jyhiuhng
31 Aug 20
Third party tender offer statement
8:46am
8-K
EX-99.1
xkzk0a3bn cfouz3f4
4 Dec 12
Regulation FD Disclosure
12:00am